EUVIMEDEUVIMED entdecken
Crossref

CUI ‐ MET : A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple‐Dose, Multiple‐Outcome Randomized Trials

Fanni Zhang iD, Kristine Broglio iD, Michael Sweeting iD, Gina D'Angelo iD

Pharmaceutical Statistics · 2026-07 · 25 (4)

DOI: 10.1002/pst.70101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 05.06.2026. Verfasst von Fanni Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Biometrics, AstraZeneca, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Antineoplastic Agents, Decision Support Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dose optimization in oncology clinical trials has shifted from solely seeking the maximum tolerated dose to identifying the Optimal Biological Dose (OBD) that balances therapeutic benefits and risks across multiple clinical attributes. Existing advanced dose‐finding methods can integrate multiple endpoints but may not be suitable to compare dose levels from randomized dose optimization studies with small sample sizes. To address these challenges, we propose a clinical utility index (CUI) based analysis and decision framework for dose optimization in multiple‐dose, multiple‐outcome randomized trials (CUI‐MET). This framework integrates multiple binary endpoints into a combined CUI for each dose level by weighting together multiple endpoints. Marginal summaries of individual endpoints can be estimated either empirically or via one or more choices of different parametric dose–response models. These estimated probabilities are then combined using endpoint‐specific weights to compute a utility score for each dose. The dose with the highest score within a prespecified clinically acceptable dose set is selected as optimal. Bootstrap analysis provides confidence intervals for the CUI and estimates the probability that each dose is selected as optimal, thereby evaluating the robustness of dose selection. To enhance usability, we implemented these methods in an interactive R Shiny application and demonstrated functionality through case examples. The framework's flexibility allows for different model selections and endpoint weighting schemes to reflect specific clinical priorities and sensitivity analyses. By integrating multiple endpoints into a single utility index and incorporating user‐friendly visualizations, CUI‐MET offers a flexible and accessible solution for dose optimization in early‐phase oncology trials, supporting informed decision‐making and the integration of patient‐relevant outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicAntineoplastic AgentsDecision Support TechniquesHumansDose-Response Relationship, DrugMaximum Tolerated DoseModels, StatisticalEndpoint DeterminationNeoplasmsTreatment Outcome

Stichwörter der Autor:innen

R shiny appclinical utility indexdose optimizationmultiple endpointsoptimal biological dose

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Oncology Biometrics, AstraZeneca, Gaithersburg, Maryland, USA.
  • Oncology Biometrics, AstraZeneca, London, UK.

ORCID-Profile: Fanni Zhang, Kristine Broglio, Michael Sweeting, Gina D'Angelo

Zitieren

APA

Zhang, F., Broglio, K., Sweeting, M., & D'Angelo, G. (2026). CUI ‐ MET : A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple‐Dose, Multiple‐Outcome Randomized Trials. Pharmaceutical Statistics, 25(4). https://doi.org/10.1002/pst.70101

Vancouver

Zhang F, Broglio K, Sweeting M, D'Angelo G. CUI ‐ MET : A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple‐Dose, Multiple‐Outcome Randomized Trials. Pharmaceutical Statistics. 2026;25(4). doi:10.1002/pst.70101

BibTeX
@article{Zhang2026,
  author = {Zhang, Fanni and Broglio, Kristine and Sweeting, Michael and D'Angelo, Gina},
  title = {CUI ‐ MET : A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple‐Dose, Multiple‐Outcome Randomized Trials},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  volume = {25},
  number = {4},
  doi = {10.1002/pst.70101}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche